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This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus 
(HCV) genotype 1 post-orthotopic liver transplant evaluated once-daily simeprevir 
150mg+sofosbuvir 400mg, with and without ribavirin 1,000mg.  Primary endpoint was 
proportion of subjects with Week 12 sustained virologic response (SVR12).  Thirty-three 
subjects without cirrhosis were randomized 1:1:1 into three arms (stratified by 
geno/subtype and Q80K): Arm 1, simeprevir+sofosbuvir+ribavirin, 12 weeks; Arm 2, 
simeprevir+sofosbuvir, 12 weeks; Arm 3, simeprevir+sofosbuvir, 24 weeks; 13 
additional subjects (2 with cirrhosis, 11 without cirrhosis) entered Arm 3.  All 46 subjects 
received at least one dose of study drug; median age, 60 years; 73.9% male; 80.4% 
white; 71.7% geno/subtype 1a (12 [36.4%] of these had Q80K); median 4.5 years post-
transplant.  Among randomized subjects, SVR12 was achieved by 81.8% in Arm 1, 
100% in Arm 2, and 93.9% in Arm 3; two subjects did not achieve SVR12: one viral 
relapse (follow-up Week 4; Arm 1) and one missing follow-up Week 12 data.  In total, 
five subjects had a serious adverse event, considered unrelated to treatment per 
investigator.  Simeprevir exposure was increased relative to the non-transplant setting, 
but not considered clinically relevant.  Simeprevir+sofosbuvir treatment, with or without 
ribavirin, was efficacious and well tolerated (ClinicalTrials.gov Identifier: NCT02165189). 
Introduction 
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and liver 
transplantation [1-3].  Compared with conventional interferon-based therapies [4-6] and 
boceprevir/telaprevir-based triple therapies [7-12], newer direct-acting antiviral agents 
have been shown to improve outcomes for liver transplant recipients with recurrent HCV 
infection [13-19].  In one study of 34 post-liver transplant recipients without cirrhosis, 
treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for 24 weeks 
resulted in a sustained virologic response 12 weeks after the end of treatment (SVR12) 
rate of 97% [13]; an SVR12 rate of 95% was seen in another study (n = 53) evaluating 
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ledipasvir/sofosbuvir + ribavirin for 12 or 24 weeks demonstrated SVR12 rates ranging 
from 96% to 98% in subjects without cirrhosis or with Child-Turcotte-Pugh (CTP) class 
A cirrhosis, 85% to 88% in subjects with CTP class B cirrhosis, and 60% to 75% in 
subjects with CTP class C cirrhosis [18].  Despite such favorable outcomes, all 
approved regimens require the use of ribavirin, which has been associated with 
safety/tolerability concerns, such as anemia, fatigue, headache, nausea, and 
hyperbilirubinemia [14,20-22].  In addition, the side effects of ribavirin may result in  
substantial healthcare costs (eg, laboratory testing, clinic visits, medication) [23]. 
 
Simeprevir is a once-daily, oral, HCV NS3/4A protease inhibitor approved in the non-
transplant setting for the treatment of chronic HCV genotype 1 infection as part of 
combination antiviral therapy [24,25].  Retrospective studies of simeprevir and 
sofosbuvir (HCV NS5B nucleotide polymerase inhibitor), with or without ribavirin, in 
HCV genotype 1–infected liver transplant recipients have demonstrated favorable 
efficacy and safety profiles over a 12-week treatment period [15-17,26,27].  The vast 
majority (73%-100%) of subjects in these studies did not receive treatment with 
ribavirin; SVR12 rates ranged from 88% to 94%.  In a real-world setting (HCV-TARGET 
registry), simeprevir and sofosbuvir treatment for 12 or 24 weeks, with or without 
ribavirin, in post-liver transplant recipients showed an SVR12 rate of 88% [28]. 
 
In this phase 2 clinical study (GALAXY; ClinicalTrials.gov Identifier: NCT02165189), the 
efficacy and safety of simeprevir in combination with sofosbuvir, with or without ribavirin, 
were evaluated in post-orthotopic liver transplant recipients with recurrent HCV 
genotype 1 infection.  The emergence of resistance-associated HCV genotype variants 
and the pharmacokinetics of simeprevir and sofosbuvir were also assessed.  These are 
the first prospective, multicenter data to be reported on post-liver transplant recipients 
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Materials and Methods  
Study Design and Population 
This was a phase 2, prospective, multicenter, randomized, open-label study that 
enrolled non-pregnant adults who were ≥18 years of age with recurrent HCV genotype 1 
infection and an HCV RNA level >10,000 IU/mL at baseline (study dates: 11 August 
2014 to 10 November 2015).  Subjects must have had a primary orthotopic liver 
transplant (living or deceased donor) ≥6 months to 15 years before enrollment, and 
were required to be on stable immunosuppression for ≥3 months before screening.  
Subjects’ renal function, as measured by the Cockcroft Gault formula, must have been 
>30 mL/min.  Assessment of liver fibrosis (liver graft biopsy or non-invasive procedure 
[29]) within 12 months of or at the screening visit, except for subjects with a diagnosis of 
cirrhosis, was required.  Key exclusion criteria included receiving treatment with a 
direct-acting antiviral drug for HCV infection (prior treatment with interferon or 
peginterferon, with or without ribavirin, was allowed if completed ≥3 months before 
screening); hepatic decompensation; and HCV NS3 resistance-associated mutations 
identified as conferring resistance to simeprevir, except Q80K. 
 
Initially, 33 subjects without cirrhosis were enrolled and randomized 1:1:1 using an 
interactive voice or web response system into one of three treatment arms; the 
randomization was balanced by using randomly permuted blocks and was stratified by 
HCV geno/subtype and NS3 polymorphism (geno/subtype 1a with Q80K versus 
geno/subtype 1a without Q80K versus geno/subtype 1b).  The study controlled for the 
use of ribavirin; the three treatment arms were as follows: Arm 1, once-daily simeprevir 
150 mg + once-daily sofosbuvir 400 mg + weight-based ribavirin (1,000 mg daily dose 
for subjects weighing <75 kg; 1,200 mg for subjects weighing ≥75 kg) for 12 weeks; Arm 
2, once-daily simeprevir 150 mg + once-daily sofosbuvir 400 mg for 12 weeks; Arm 3, 
once-daily simeprevir 150 mg + once-daily sofosbuvir 400 mg for 24 weeks.  Upon 
completion of randomization, enrollment into Arm 3 was opened to all eligible subjects, 
regardless of the presence of cirrhosis, until a total of 46 subjects were enrolled; this 
allowed subjects with cirrhosis to enter the study and receive the recommended 24 
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six weeks and treatment was followed by a 12-week post-treatment follow-up period.  
Study drugs were discontinued for subjects with viral breakthrough.  Choice of 
immunosuppressant was at the investigator’s discretion, excluding cyclosporine due to 
a potential pharmacokinetic interaction with simeprevir [24,25].  See Supporting 
Information for further study design and population details. 
 
The study protocol was reviewed by an institutional review board.  This study was 
conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and that are consistent with Good Clinical Practices and 
applicable regulatory requirements.  Subjects provided written informed consent to 
participate in the study.   
 
Efficacy Assessments 
The primary efficacy endpoint was the proportion of subjects who achieved SVR12.  
Secondary efficacy endpoints were on-treatment virologic response at Weeks 2, 4, 8, 
and 12 (all subjects) and Weeks 16, 20, and 24 (subjects in Arm 3); the proportion of 
subjects who achieved sustained virologic response four weeks after the end of 
treatment (SVR4); and the incidence of virologic breakthrough and relapse.  In addition, 
subgroup analyses were performed for SVR12 rates based on subject characteristics, 
including presence of baseline HCV polymorphisms (NS3 Q80K and NS5A positions of 
interest; Supporting Information) and use of gastric acid-reducing agents.  The latter 




Samples were collected at baseline and at the time of virologic failure during therapy to 
monitor for the emergence of HCV resistance-associated variants, with sequencing of 
HCV NS3, NS5A, and NS5B polymorphisms at baseline and NS3 and NS5B resistance-
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Pharmacokinetic Assessments 
Pharmacokinetic sampling of simeprevir and GS-331007 (the major sofosbuvir 
metabolite [31]; hereinafter referred to as “sofosbuvir” for simplicity) trough levels 
occurred on Days 28, 56, and 84 for all subjects and also on Day 168 for subjects in 
Arm 3.  The following parameters were assessed: trough plasma concentration (Ctrough), 
maximum plasma concentration (Cmax), average steady-state plasma concentration 
(Css,av), and area under the concentration-time curve from time of administration to 24 
hours post-dose (AUC24h
 
).  The model-predicted relationship between creatinine 
clearance at baseline and the central clearance of sofosbuvir, and the relationship 
between creatinine clearance at baseline and exposure to sofosbuvir (smoothing line 
computed using loess smoothing, implemented in R-software), were also evaluated. 
Blood samples for the determination of immunosuppressant plasma concentrations 
were collected twice during the first week of treatment, weekly during the next three 
weeks, and per local institutional protocol thereafter.  Immunosuppressant dose 
adjustments during therapy were also described. 
 
Safety Assessments 
Safety evaluations included monitoring of adverse events (AEs; for severity grading, see 
Supporting Information), clinical laboratory tests, vital sign measurements, and 
physical examinations.  Diagnosis of rejection was to be made by a local pathologist per 
institution protocol. 
 
Patient-reported Outcomes (PROs) 
PROs were assessed using two validated instruments: the EuroQoL 5-Dimensions (EQ-
5D) questionnaire [32] and the Hepatitis C Symptom and Impact Questionnaire version 
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Statistical Analyses 
The intent-to-treat (ITT) population was defined as all subjects who took at least one 
dose of study drug.  Within the ITT population, randomized subjects were evaluated for 
efficacy and PRO outcomes.  Pharmacokinetics and safety were evaluated in all ITT 
subjects.  SVR12 rates were tabulated per treatment arm.  For determination of sample 
size, with a target SVR12 rate of 80%, 11 subjects would have allowed the SVR12 rate 
to be estimated in Arms 1 and 2 with a two-sided 95% confidence interval (CI; 
calculated using a normal approximation with continuity correction) width of 50.8%; 
thus, 80% (46.3%, 97.1%) and 23 subjects in Arm 3 would have allowed the SVR12 
rate to be estimated with a two-sided 95% CI width of 35.3%, thus 80% (58.2%, 93.6%). 
 
Secondary endpoints were summarized using descriptive statistics; SVR4, viral 
breakthrough, and viral relapse were tabulated per treatment arm.  Relevant changes in 
viral sequence in the HCV NS3 and NS5B regions were summarized.  Pharmacokinetic 
analyses included all subjects who underwent pharmacokinetic sampling at any point 
during the study.  Descriptive statistics are provided for the pharmacokinetic parameters 
of immunosuppressants, simeprevir, and sofosbuvir; for simeprevir and sofosbuvir, 
parameters were analyzed using a Bayesian feedback analysis (Supporting 
Information).  PRO endpoints were analyzed using descriptive statistics; mean and 




A total of 66 individuals were screened; 20 of these individuals were excluded due to 
not meeting ≥1 of the inclusion criteria, while 46 were enrolled in the study and took at 
least one dose of study drug (Figure 1).  Among all subjects, the median (range) age 
was 60.0 (49-68) years and the majority were male (73.9%) and white (80.4%; Table 1).  
Two (4.3%) subjects had cirrhosis, and the median time since liver transplant was 4.5 
years.  Of the 33 (71.7%) subjects with HCV geno/subtype 1a, 12 (36.4%) had Q80K.  
The baseline median HCV RNA was ~6,650,000 IU/mL and 80.4% of all subjects had 
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disease (ie, METAVIR grade A1 [45.7%] or A2 [26.1%] and METAVIR fibrosis stage 
F0/F1 [19.6%] or F2 [50.0%]). 
 
Overall, 44 subjects (95.7%) completed study drug and 43 subjects (93.5%) completed 
the study.  For the 33 randomized subjects, the median (range) actual treatment 
durations were as follows: Arm 1, 12.0 (8.9-12.1) weeks; Arm 2, 12.0 (11.3-13.0) weeks; 
Arm 3, 24.0 (24.0-25.6) weeks.   
 
Efficacy  
On-treatment virologic response over time among randomized subjects is shown in 
Figure 2A.  SVR12 was achieved by 31 of 33 randomized subjects (93.9%), including 
nine of 11 (81.8%) in Arm 1, 11 of 11 (100%) in Arm 2, and 11 of 11 (100%) in Arm 3 
(Figure 2B); the same virologic response rates were observed at the SVR4 time point.  
One subject did not achieve SVR12 due to viral relapse (at follow-up Week 4; see 
below) and another for non-virologic reasons (suicide). 
 
For randomized subjects who had HCV geno/subtype 1a infection and Q80K 
polymorphism data, the SVR12 rate was 100% (9/9; 95% CI, 66.4%-100%) for those 
with the Q80K polymorphism and 85.7% (12/14; 95% CI, 57.2%-98.2%) for those 
without.  The SVR12 rate was 90.0% (18/20; 95% CI, 68.3%-98.8%) for subjects with 
an NS5A polymorphism and 100% (11/11; 95% CI, 71.5%-100%) for those without.  
The SVR12 rate was 95.0% (19/20; 95% CI, 75.1%-99.9%) for subjects who used 
gastric acid-reducing agents and 92.3% (12/13; 95% CI, 64.0%-99.8%) for those who 
did not. 
 
No subjects experienced viral breakthrough.  One subject in Arm 1 experienced viral 
relapse at the follow-up Week 4 time point.  This subject was a 53-year-old white male 
with a body mass index of 29 kg/m2, baseline viral load of 4,130,000 IU/mL, HCV 
geno/subtype 1a without NS3 Q80K, and METAVIR score F2.  It had been 7.7 years 
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categorized as “no response”; there were no emerging HCV NS3 or NS5B mutations at 
the time of failure.  No other subjects had resistance testing performed. 
   
Pharmacokinetic Assessments 
Exposures to both simeprevir and sofosbuvir were similar across treatment arms among 
all subjects (Table 2).  A correlation between sofosbuvir exposure and creatinine 
clearance was observed; central clearance of sofosbuvir increased with increasing 
creatinine clearance at baseline, and exposure to sofosbuvir (AUC/Cmax
 
) increased with 
decreasing creatinine clearance (Figure 3). 
Safety 
Overall, most subjects (97.8%) reported an AE during the treatment phase; AEs were 
balanced across treatment groups (Table 3).  The most common AEs (>25% of total 
population) during treatment were headache (37.0%) and fatigue (34.8%).  Five (10.9%) 
subjects had serious AEs, including one that was fatal (suicide); none were considered 
by the investigator to be related to study drug.  Two AEs occurred during treatment that 
were grade ≥2 in severity and considered possibly related to simeprevir: fatigue and 
increased gamma-glutamyltransferase.  One transplant rejection occurred at follow-up 
Week 12 in Arm 3.  Of note, this subject’s tacrolimus plasma level fell from 13.8 µg/L at 
baseline to 3.2 µg/L at the time of rejection.  Treatment-induced resolution occurred 
within six days. 
 
Four (8.7%) subjects had an AE of photosensitivity (one subject in Arm 2 and three 
subjects in Arm 3); all events were grade 1 in severity.  Three (6.5%) subjects, all in 
Arm 1, had anemia; no growth factors were used for treatment.  There were four 
laboratory parameters for which at least one subject had an abnormality with grade 3 
severity, including amylase level (two subjects; one each in Arms 2 and 3), gamma-
glutamyltransferase (one subject; Arm 3), hyperbilirubinemia (one subject; Arm 1), and 
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Tacrolimus plasma levels over time are shown in Figure 4.  A dose adjustment of 
immunosuppressants (any time during the study) occurred in 15 of 46 (32.6%) subjects: 
five in Arm 1, one in Arm 2, and nine in Arm 3.  For one subject in Arm 3, 
mycophenolate mofetil was discontinued at screening, and tacrolimus was continued 
unchanged.  For two subjects, either the original or new dose was not known (but both 
were counted as having a dose adjustment).  Apart from these dose adjustments, there 
were no other changes in immunosuppressant regimens. 
 
PROs 
The mean HCV-SIQv4 overall body system score at baseline was similar across 
treatment arms for randomized subjects, and there were minimal changes from baseline 
to follow-up Week 12 (Table S1).  At baseline, the mean EQ-5D visual analog scale 
(VAS) score was comparable across treatment arms (Table S2).  These scores 
fluctuated over time; the changes were not considered clinically important, with the 
exception of a small improvement in EQ-5D VAS score at follow-up Week 12 for 
subjects in Arm 3.  Median changes from baseline over time are shown in Figure S1.  
Overall, there were no clear patterns of improvement or worsening in scores over time 
or differences between treatment arms in PRO data. 
 
Discussion 
GALAXY is the first prospective, multicenter study that evaluated simeprevir and 
sofosbuvir treatment, with or without ribavirin, in the transplant setting.  This regimen 
was efficacious in liver transplant recipients with recurrent HCV genotype 1 infection, 
consistent with results in a non-transplant setting [33].  SVR12 was achieved by 81.8% 
of subjects in Arm 1, 100% in Arm 2, and 100% in Arm 3.  The relatively lower SVR12 
rate in Arm 1 versus Arms 2 and 3 was due to missing data from one subject (9.1%).  
The efficacy of simeprevir in this population was further supported by on-treatment 
virologic response data.  No subjects had viral breakthrough and only one subject (Arm 
1) had viral relapse.  For these subjects, the majority of whom did not have cirrhosis, 
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regardless of the presence of Q80K, consistent with results in the non-transplant setting 
[33].   
 
It is clinically important that all subjects (11/11) treated with a ribavirin-free regimen of 
simeprevir and sofosbuvir for 12 weeks achieved SVR12 because most liver transplant 
recipients tolerate ribavirin poorly and some cannot tolerate ribavirin at any dose 
[14,21].  Furthermore, simeprevir and sofosbuvir, with or without ribavirin, is an HCV 
NS5A inhibitor-free regimen; as NS5A inhibitors have a low barrier to resistance and 
variants tend to persist, this regimen may be an option for individuals with HCV NS5A 
variants [34-36].  Notably, most GALAXY subjects had an HCV NS5A polymorphism 
and the presence of these polymorphisms did not have a substantial impact on SVR12 
achievement.  
 
Evaluation of potential pharmacokinetic interaction between antiviral agents and 
commonly used concomitant medications is important and for post-transplant recipients, 
immunosuppressant use is of particular interest.  In a previous study of post-liver 
transplant recipients (SATURN), simeprevir exposure was increased 581% during 
concomitant cyclosporine A use; based on this, cyclosporine A is not recommended for 
coadministration with simeprevir [24].  The same study showed a 185% increase in 
simeprevir exposure with concomitant tacrolimus use, but this result was not considered 
clinically significant [24].  Based on these findings, the current study did not allow for 
use of cyclosporine A. 
 
The GALAXY study is the first to describe steady-state simeprevir and sofosbuvir 
exposures in post-liver transplant recipients with HCV genotype 1 infection.  Subjects’ 
exposures to these agents were similar regardless of treatment arm; however, 
compared with similar data collected in a non-transplant setting (COSMOS study) [33], 
exposures were numerically higher (simeprevir AUC24h values were 26,820 and 44,300 
ng·h/mL, and sofosbuvir AUC24h values were 10,801 and 17,884 ng·h/mL, in COSMOS 
and GALAXY, respectively).  Given the large variability in the current study, these 
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increase in simeprevir exposure may be due, in part, to a mild pharmacokinetic 
interaction between simeprevir and tacrolimus [24].  The lack of a clinically relevant 
change in sofosbuvir exposure is consistent with previous findings in post-transplant 
recipients and healthy volunteers [14,31]. 
 
Simeprevir and sofosbuvir treatment, with or without ribavirin, was generally well 
tolerated, consistent with previous reports in this population [15-17,26,27].  Safety 
outcomes were comparable across arms, and not unexpectedly, anemia was only 
observed in subjects treated with ribavirin [15,26,27].  There were few serious AEs and 
only two subjects had an AE that was grade ≥2 and considered possibly related to 
simeprevir.  One transplant rejection occurred at follow-up Week 12; consistent with 
this, the subject’s tacrolimus level had markedly decreased from baseline to the time of 
rejection.  A gradual downward trend in tacrolimus levels was observed in subjects 
using tacrolimus, similar to what has been noted in another study of simeprevir and 
sofosbuvir in this patient population [15].  Decreased tacrolimus levels may be 
explained by the reduced tacrolimus exposure with simeprevir coadministration that was 
previously observed in healthy volunteers.[37]  It is also possible that subjects’ liver 
function improved during effective HCV therapy, leading to HCV RNA clearance and 
subsequently increased tacrolimus metabolism [38].  Caution should be used when 
interpreting these tacrolimus pharmacokinetic results given the small numbers of 
subjects with available data at each time point and the overlapping CIs.   
 
PRO endpoints were evaluated to describe the severity of symptoms associated with 
HCV or its treatment and health-related quality of life before and after treatment during 
the current GALAXY study.  At baseline, subjects reported overall symptom severity and 
health-related quality of life measures that were similar to what’s been reported in the 
non-transplant setting for HCV genotype 1–infected subjects without cirrhosis or with 
compensated cirrhosis [39].  In that study of non-transplant subjects, symptom scores 
improved with simeprevir and sofosbuvir treatment by the follow-up Week 12 visit, 
sometimes by amounts considered clinically important.  In the post-transplant GALAXY 















This article is protected by copyright. All rights reserved 
and the median change in EQ-5D VAS scores indicated an improvement that was 
slightly less than the value that has been shown to be clinically important in all cases 
except in Arm 3 subjects at the follow-up Week 12 time point, at which point a small but 
clinically significant improvement was observed. 
 
A limitation of the current study is the small sample size, which necessitated descriptive 
statistics and limited comparisons between treatment groups.  For example, there was 
one subject who had missing data in the randomized population; this subject 
represented 9.1% of the Arm 1 population and significantly impacted the SVR12 rate in 
this treatment group (as noted above).  Another limitation is that the majority of subjects 
had less advanced disease (METAVIR score F0-F2), which has been associated with 
higher SVR12 rates in previous studies in HCV genotype 1–infected liver transplant 
recipients [13,15,16].  However, it is also possible that disease severity was 
underestimated in some cases, as assessment of liver fibrosis could have occurred up 
to 12 months prior to screening. 
 
In summary, the GALAXY study demonstrated the efficacy and safety of simeprevir and 
sofosbuvir treatment, with or without ribavirin, for 12 or 24 weeks in post-orthotopic liver 
transplant recipients with recurrent HCV genotype 1.  These regimens may be clinically 
important options for individuals with NS5A variants and, importantly, 100% of subjects 
treated with simeprevir and sofosbuvir for 12 weeks achieved SVR12, suggesting that 
this regimen may be adequate for individuals without cirrhosis.  Further study is 
warranted to determine whether this therapy is also efficacious in patients with cirrhosis. 
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Figure Legends 
Figure 1.  Subject disposition. 
Subject disposition during the treatment and follow-up periods of the GALAXY study. 
SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin. 
aSuicide, considered unrelated to study drug by the investigator. 
b
 
Subject had metastatic prostate cancer. 
Figure 2.  Virologic response over time.  A. On-treatment virologic response.  B. 
SVR12. 
Virologic response was assessed in randomized subjects at on-treatment Weeks 2, 4, 
8, and 12, and EOT.  SVR was defined as HCV RNA <15 IU/mL (detectable or 
undetectable). 
HCV, hepatitis C virus; LLQ, lower limit of quantitation; EOT, end of treatment; SVR12, 
sustained virologic response 12 weeks after the end of treatment; CI, confidence 
interval; SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin. 
aArm 1, n = 11; Arm 2, n = 11; Arm 3, n = 11. 
bArm 1, n = 9; Arm 2, n = 10; Arm 3, n = 11. 
c
 
For the two subjects who did not achieve SVR12, one committed suicide and one had 
viral relapse. 
 
Figure 3.  Correlation between sofosbuvir exposure and creatinine clearance. 
On the left, central clearance of sofosbuvir is plotted against creatinine clearance at 
baseline.  On the right, sofosbuvir exposure is plotted against creatinine clearance.  
AUC, area under the concentration-time curve. 
 
Figure 4.  Tacrolimus plasma levels over time.
Median (range) tacrolimus plasma levels are plotted over time for subjects who used 
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aMedian (range) levels were as follows: baseline, 6.50 (2.0-18.6) IU/mL; Week 12, 4.90 
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Table 1.  Baseline Demographic and Disease Characteristics  
 
Total 
(N = 46) 
Arm 1:  
SMV + SOF 
+ RBV,      
12 wk 
(n = 11) 
Arm 2:  
SMV + SOF,     
12 wk 
(n = 11) 
Arm 3:  
SMV + SOF, 
24 wk 
(n = 11) 
Arm 3 
nonrand: 
SMV + SOF, 
24 wk 
(n = 13) 
Gender, n (%)      
Male 34 (73.9) 8 (72.7) 8 (72.7) 7 (63.6) 11 (84.6) 
Female 12 (26.1) 3 (27.3) 3 (27.3) 4 (36.4) 2 (15.4) 
Race, n (%)      
White 37 (80.4) 9 (81.8) 9 (81.8) 7 (63.6) 12 (92.3) 
Black/African 
American 
8 (17.4) 1 (9.1) 2 (18.2) 4 (36.4) 1 (7.7) 
Asian 1 (2.2) 1 (9.1) 0 0 0 
Ethnicity, n (%)a      
Hispanic/Latino 3 (6.5) 0 1 (9.1) 2 (18.2) 0 
Not 
Hispanic/Latino 
43 (93.5) 11 (100) 10 (90.9) 9 (81.8) 13 (100) 
Age, median 
(range), y 
60.0        
(49-68) 
60.0        
(53-65) 
59.0        
(50-68) 
61.0        
(49-64) 




28.8     
(20.5-43.4) 
28.8     
(22.5-34.5) 
28.1     
(24.8-40.4) 
28.8     
(20.5-43.4) 
















This article is protected by copyright. All rights reserved 
 
Total 
(N = 46) 
Arm 1:  
SMV + SOF 
+ RBV,      
12 wk 
(n = 11) 
Arm 2:  
SMV + SOF,     
12 wk 
(n = 11) 
Arm 3:  
SMV + SOF, 
24 wk 
(n = 11) 
Arm 3 
nonrand: 
SMV + SOF, 
24 wk 
(n = 13) 
Use of gastric acid-
reducing agent, n 
(%)b 
28 (60.9) 5 (45.5) 8 (72.7) 7 (63.6) 8 (61.5) 
Presence of 
cirrhosis, n (%) 
2 (4.3) – – – 2 (15.4) 
METAVIR stage, n 
(%)a 
     
F0/F1 9 (19.6) 2 (18.2) 1 (9.1) 1 (9.1) 5 (38.5) 
F2 23 (50.0) 8 (72.7) 6 (54.5) 6 (54.5) 3 (23.1) 
F3 9 (19.6) 1 (9.1) 3 (27.3) 4 (36.4) 1 (7.7) 
F4 1 (2.2) 0 0 0 1 (7.7) 
Missing 4 (8.7) 0 1 (9.1) 0 3 (23.1) 
Time since liver 
transplant, median 
(range), y 
4.5         
(0.8-14.3) 
6.0         
(1.1-10.3) 
5.5         
(1.9-14.3) 
4.8         
(2.3-7.5) 
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Total 
(N = 46) 
Arm 1:  
SMV + SOF 
+ RBV,      
12 wk 
(n = 11) 
Arm 2:  
SMV + SOF,     
12 wk 
(n = 11) 
Arm 3:  
SMV + SOF, 
24 wk 
(n = 11) 
Arm 3 
nonrand: 
SMV + SOF, 
24 wk 
(n = 13) 
Mycophenolate 
mofetil 
19 (41.3) 4 (36.4) 4 (36.4) 6 (54.5) 5 (38.5) 
Sirolimus 5 (10.9) 1 (9.1) 2 (18.2) 1 (9.1) 1 (7.7) 
HCV geno/subtype 
and NS3 Q80K 
polymorphism, n 
(%)d 
     
1a 33 (71.7) 8 (72.7) 7 (63.6) 8 (72.7) 10 (76.9) 
Q80K 12 (36.4) 3 (37.5) 4 (57.1) 2 (25.0) 3 (30.0) 
No Q80K 20 (60.6) 5 (62.5) 3 (42.9) 6 (75.0) 6 (60.0) 
1b 13 (28.3) 3 (27.3) 4 (36.4) 3 (27.3) 3 (23.1) 
HCV NS5A 
polymorphism at 
position of interest, n 
(%)a,e  
     
No 14 (30.4) 2 (18.2) 5 (45.5) 4 (36.4) 3 (23.1) 
Yes 28 (60.9) 8 (72.7) 5 (45.5) 7 (63.6) 8 (61.5) 
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Total 
(N = 46) 
Arm 1:  
SMV + SOF 
+ RBV,      
12 wk 
(n = 11) 
Arm 2:  
SMV + SOF,     
12 wk 
(n = 11) 
Arm 3:  
SMV + SOF, 
24 wk 
(n = 11) 
Arm 3 
nonrand: 
SMV + SOF, 
24 wk 
(n = 13) 
HCV NS5B 
polymorphism at 
position of interest,  
n (%)a,f  
     
No 36 (78.3) 10 (90.9) 8 (72.7) 11 (100) 7 (53.8) 
Yes 5 (10.9) 0 3 (27.3) 0 2 (15.4) 
Not available 5 (10.9) 1 (9.1) 0 0 4 (30.8) 
HCV RNA viral load, 
median (range), 
log10 IU/mL 
6.6         
(4.1-7.6) 
6.6         
(5.6-7.0) 
6.6         
(6.3-7.1) 
6.7         
(6.0-7.6) 
5.8         
(4.1-7.5) 
SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin; nonrand, nonrandomized subgroup; 
BMI, body mass index; HCV, hepatitis C virus. 
aPercentages may not total 100% due to rounding. 
bUse of prescription or over-the-counter medications at any time.  
cImmunosuppressant use at screening. 
dHCV NS3 Q80K polymorphism data not available for 1 subject in the nonrandomized 
subgroup of Arm 3.   
eHCV NS5A amino acid positions of interest included 23, 24, 28, 30, 31, 32, 38, 54, 56, 
58, 62, 64, 92, and 93. 
fHCV NS5B amino acid positions of interest included 96, 142, 159, 282, 316, 320, 321, 
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Table 2.  Summary of Pharmacokinetic Parameters 
 
Total 
(N = 46) 
Arm 1: 
SMV + SOF + 
RBV, 12 wk 
(n = 11) 
Arm 2: 
SMV + SOF,  
12 wk 
(n = 11) 
Arm 3: 
SMV + SOF, 24 
wk 
(n = 24) 
SMVa     
Ctrough, median 
(range), ng/mL 
1,055          
(110-16,400) 
1,010          
(157-4,110) 
1,190          
(110-12,300) 




2,945           
(630-21,000) 
3,050           
(630-7,970) 
3,040           
(975-17,100) 




1,846           
(353-18,972) 
1,883           
(353-5,792) 
1,854           
(416-14,542) 




44,300           
(8,460-451,000) 
45,200           
(8,460-139,000) 
44,500           
(9,980-349,000) 
40,850          
(10,400-451,000) 
Sofosbuvirb     
Ctrough, median 
(range), ng/mL 
518              
(91-1,317) 
534             
(249-1,193) 
442              
(91-1,061) 




1,249           
(354-2,665) 
1,294           
(450-2,411) 
1,124          
(354-2,215) 




745             
(295-1,777) 
787             
(341-1,612) 
672            
(295-1,458) 




17,884          
(7,087-42,647) 
18,899          
(8,191-38,682) 
16,129          
(7,087-34,995) 
19,884          
(10,777-42,647) 
SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin; Ctrough, trough plasma concentration; 
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concentration; AUC24h, area under the plasma concentration-time curve from time of 
administration to 24 hours post-dose. 
aIn total, 152 plasma samples from 46 subjects were available for analysis (of the 159 
samples in the dataset, two were below the lower limit of quantitation and five were 
excluded because the intake time of the dose taken prior to the sample was missing). 
bIn total, 153 plasma samples from 46 subjects were available for analysis (of the 159 
samples in the dataset, one was below the lower limit of quantitation and five were 
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Table 3.  Summary of Safety During the Treatment Phase  
 
Total 
(N = 46) 
Arm 1: SMV 
+ SOF + 
RBV, 12 wk 
(n = 11) 
Arm 2: SMV 
+ SOF, 12 
wk 
(n = 11) 
Arm 3: SMV 
+ SOF, 24 
wk 
(n = 11) 
Arm 3 
nonrand: 
SMV + SOF, 
24 wk 
(n = 13) 
Any AE, n (%) 45 (97.8) 11 (100) 11 (100) 11 (100) 12 (92.3) 
Any serious AE, 
n (%)a 
5 (10.9) 2 (18.2) 0 1 (9.1) 2 (15.4) 
Any fatal AE, 
n (%)b 
1 (2.2) 1 (9.1) 0 0 0 
AE at least 
possibly related 
to SMV, n (%) 
29 (63.0) 7 (63.6) 9 (81.8) 7 (63.6) 6 (46.2) 
Grade ≥2c 2 (4.3) 0 0 0 2 (15.4) 
AE leading to 
permanent 
discontinuation 
of ≥1 study 
drug, n (%)d 
2 (4.3) 2 (18.2) 0 0 0 
Most common 
AEs, n (%)e,f 
     
Headache 17 (37.0) 5 (45.5) 3 (27.3) 7 (63.6) 2 (15.4) 
Fatigue 16 (34.8) 3 (27.3) 3 (27.3) 5 (45.5) 5 (38.5) 
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Diarrhea 10 (21.7) 2 (18.2) 3 (27.3) 3 (27.3) 2 (15.4) 
Pruritus 10 (21.7) 4 (36.4) 4 (36.4) 2 (18.2) 0 
Vomiting 8 (17.4) 2 (18.2) 2 (18.2) 2 (18.2) 2 (15.4) 
Dyspnea 7 (15.2) 2 (18.2) 2 (18.2) 3 (27.3) 0 
Decreased 
appetite 
6 (13.0) 2 (18.2) 2 (18.2) 2 (18.2) 0 
Insomnia 6 (13.0) 3 (27.3) 1 (9.1) 1 (9.1) 1 (7.7) 
Rashg 6 (13.0) 3 (27.3) 1 (9.1) 2 (18.2) 0 
Constipation 5 (10.9) 2 (18.2) 2 (18.2) 1 (9.1) 0 
SMV, simeprevir; SOF, sofosbuvir; RBV, ribavirin; nonrand, nonrandomized subgroup; 
AE, adverse event. 
aNone of the serious AEs were considered to be possibly related to study drug by the 
investigator.  The serious AEs were as follows: Arm 1, device-related infection and 
completed suicide; Arm 3, small intestinal obstruction (randomized subgroup), 
abdominal hernia (nonrandomized subgroup), and prostate cancer (nonrandomized 
subgroup). 
bOne subject committed suicide, considered unrelated to study drug by the investigator.  
cAEs were fatigue and increased gamma glutamyltransferase. 
dOne subject committed suicide and discontinued all three study medications; a second 
subject discontinued ribavirin due to anemia. 
eReported by >10% of subjects in total population by preferred term. 
fOne (2.2%) subject had a photosensitivity reaction AE by preferred term, and a total of 
four (8.7%) subjects had a photosensitivity condition AE of clinical interest (including the 
following preferred terms: photosensitivity reaction and sunburn).  All events were grade 
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gA total of ten (21.7%) subjects had a rash AE of clinical interest (including the following 
preferred terms: rash, sunburn, cutaneous vasculitis, palmar erythema, photosensitivity 
reaction, and vesicular rash).  All events were grade 1 in severity.  
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